Altimmune (ALT) recently released pemvidutide's 48-week topline results from their IMPACT Phase IIb trial, which revealed the drug's ability to continue improvement for several non-invasive fibrosis ...
Lee Roth - Burns McClellan, Inc. Thanks, operator. As a reminder, a press release summarizing the results of the trial can be found on the Investor Relations section of the company's website. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results